NEW REIMAGINED IDENTITY LIFESCIENCES AUSTRALIA REPOSITIONS FOR SECTOR Commences new initiatives in Company Directors training, Standards push and support for Early Career Stage workforce
With
Dr Tim Boyle PhD ChMPP,
Chief Executive Officer
LifeSciences Australia (formerly called ARCS Australia)
SEGMENT
Filmed in Sydney | June 2026
In June 2026, ARCS Australia formally became LifeSciences Australia — a name chosen to reflect the role the organisation plays across Australia’s life sciences sector.
Over more than 40 years, ARCS has grown well beyond its origins as a training and education body for regulatory and clinical specialists. Today, the organisation supports professionals across the entire life sciences sector — from early research through regulation, development and commercialisation — through an expanding range of programs and initiatives.
Following extensive member and stakeholder consultation throughout 2025 the name change was decided aiming to be a clearer, more inclusive identity reflecting the full breadth of Australia’s life sciences workforce and its role as the sector’s professional peak body.
Australian Health Journal was invited to the 2026 ARCS Conference in Sydney and met with Dr Tim Boyle Chief Executive Officer, LifeSciences Australia.
Source: Adapted from the ARCS Australia website
-
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.
-
Study reveals socioeconomic barriers to children’s healthcare access
Research published in the Australian Journal of General Practice (AJGP) has revealed mental health and developmental–behavioural issues such as ADHD are the most common paediatric referrals in metropolitan general practices.
But the research also revealed children at higher risk are less likely to get the care they may need.
-
Using human skin hair follicles to treat Alzheimer’s disease
Professor Michael Valenzuela is a science opinion leader, innovator and creative thinker with a career-long commitment to the prevention and treatment of dementia.
Following that he completed graduate medicine and medical training at the Prince of Wales Hospital. In 2012, he established the Regenerative Neuroscience Group at the University of Sydney, and in 2017 became the university’s first Professor of Regenerative Medicine.
Professor Valenzuela’s group discovered a new cell type with potential for regenerative medicine, a rare neural precursor cell found deep within the human hair follicle. He is the main inventor on several related patents and is the Founder and Chief Scientific Officer of Skin2Neuron – a biotech company developing the first neurorestorative cell therapy for Alzheimer’s disease based on this work.
